Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial
Mehdi Mohamadi
Mehdi Mohamadi

Assistant Professor of Medical Immunology

Department Immunology

School of Medicine

Tehran University of Medical Sciences

All Documents